奥沙利铂联合卡培他滨治疗晚期直肠癌的临床观察  

Clinical Observation of Advanced Rectal Cancer Treated with Oxaliplatin Combined Capecitabine

作　　者：孟宪禄[1] 沈元方 

机构地区：[1]河南省渑池县人民医院,河南渑池472400

出　　处：《中国医学创新》2012年第30期17-18,共2页Medical Innovation of China

摘　　要：目的:探讨及评价奥沙利铂(L-OHP)联合卡培他滨(Capecitabine,希罗达)治疗晚期直肠癌的客观疗效及毒性反应。方法:回顾性分析23例经病理证实均为晚期直肠癌患者的临床资料。具体用法:奥沙利铂130mg/m2,静脉滴注2h,d1;卡培他滨1000mg/m2,口服,2次/d,d1～14。21d为1周期,化疗2个或2个周期以上评价疗效及其毒性反应。结果:23例患者均可评价疗效,CR4例,PR11例,SD5例,PD3例,有效率(RR)为65.21%(15/23);肿瘤中位进展时间为8.2个月。毒性反应主要为骨髓抑制、神经毒性及腹泻。结论:奥沙利铂联合卡培他滨治疗晚期直肠癌有相对较好疗效,毒副反应可以耐受,用药安全,值得临床进一步推广。Objective：To evaluate the efficacy and toxicity of advanced rectal cancer treated with oxaliplatin combined capecitabine.Method：23 patients with locally advanced rectal cancer were retrospectively analyzed.Advanced rectal cancer basede chemotherapy received oxaliplatin（130 mg/m2 iv gtt）on day 1 and capecitabine（1000 mg/m2 po bid）on day 1 to 14,the regimen was repeated every 3 weeks and efficacy and toxicity were evaluated after 2 cycles.Result：In 23 evaluable patients,4 cases had completed response,11 cases had partial response,5 cases had stable disease and 3 cases with progressive disease.The response rate of the whole group was 65.21%.Median time to progression was 7.2 months.The main toxicities were myelosuppression,neutropenia and diarrhea.Conclusion：The regimen oxaliplatin combined capecitabine for advanced rectal cancer show more effectiveness and all adverse reactions are tolerable,which is worthy of further clinical research.

关 键 词：晚期直肠癌 奥沙利铂 卡培他滨 化学治疗 

分 类 号：R735.37[医药卫生—肿瘤]